Page last updated: 2024-12-11

7-fluoro-2-phenyl-4-quinolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-fluoro-2-phenyl-4-quinolone: structure given in first source; interacts with tubulin and prevents colchicine binding to tubulin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5744443
CHEMBL ID279539
SCHEMBL ID9389628
SCHEMBL ID6667030
MeSH IDM0216413

Synonyms (25)

Synonym
KUC100233 ,
bdbm50044969
7-fluoro-2-phenyl-1h-quinolin-4-one
smr000129057
MLS000517827 ,
KUC100233N
CHEMBL279539 ,
NCGC00247323-01
7-fluoro-2-phenylquinolin-4(1h)-one
147197-81-7
4(1h)-quinolinone, 7-fluoro-2-phenyl-
7-fluoro-2-phenyl-4-quinolone
HMS2204F20
HMS3345K01
825620-25-5
7-fluoro-2-phenyl-4-quinolinol
SCHEMBL9389628
mfcd11505231
7-fluoro-4-hydroxy-2-phenylquinoline
SCHEMBL6667030
DTXSID70420892
EN300-7462288
7-fluoro-2-phenyl-1,4-dihydroquinolin-4-one
CS-0260149
7-fluoro-2-phenylquinolin-4-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.63100.044717.8581100.0000AID485294
glp-1 receptor, partialHomo sapiens (human)Potency1.00000.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency0.97620.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency6.30960.00527.809829.0929AID588855
IDH1Homo sapiens (human)Potency2.59290.005210.865235.4813AID686970
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency0.02820.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency0.02820.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency0.02820.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency1.10980.004611.374133.4983AID624296; AID624297
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency1.58490.058010.694926.6086AID602310
lamin isoform A-delta10Homo sapiens (human)Potency5.01190.891312.067628.1838AID1487
Guanine nucleotide-binding protein GHomo sapiens (human)Potency6.30961.995325.532750.1187AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin beta-2B chainBos taurus (cattle)IC50 (µMol)3.70000.25001.88388.7000AID214013
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
microtubule-based processTubulin beta-2B chainBos taurus (cattle)
nervous system developmentTubulin beta-2B chainBos taurus (cattle)
positive regulation of axon guidanceTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
GTPase activityTubulin beta-2B chainBos taurus (cattle)
metal ion bindingTubulin beta-2B chainBos taurus (cattle)
protein heterodimerization activityTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID78810Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human ileocecal carcinoma HCT-8 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID152256Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in murine leukemia P-388 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID214013Inhibition of tubulin polymerization1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID214186Percentage inhibition of colchicine binding(1:1 ratio of inhibitor: colchicine)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID83787Inhibition of in vitro cell growth which reduces cell growth to level at start of experiment in colon HT-29 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID94842Inhibition of in vitro cell growth which reduces cell growth to level at start of experiment in colon KM-20L2 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID83772Inhibition of in vitro cell growth which reduces cell growth to 50% of level at start of experiment in colon HT-29 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID79789Inhibition of in vitro cell growth which reduces cell growth to 50% of level at start of experiment in colon HCC2998 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID8850Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID46470Inhibition of in vitro cell growth which reduces cell growth to level at start of experiment in colon COLO-205 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID214185Percentage inhibition of colchicine binding(10:1 ratio of inhibitor: colchicine)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID79796Inhibition of in vitro cell growth which reduces cell growth to level at start of experiment in colon HCC2998 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID95516Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human epidermoid carcinoma KB cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID46467Inhibition of in vitro cell growth which reduces cell growth to 50% of level at start of experiment in colon COLO-205 cell line (<-4 in one experiment, >-4 in other experiment)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID167040Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human melanoma RPMI-7951 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID94841Inhibition of in vitro cell growth which reduces cell growth to 50% of level at start of experiment in colon KM-20L2 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID201301Inhibition of in vitro cell growth which reduces cell growth to level at start of experiment in CNS SF-539 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID94725Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in murine leukemia L-1210 cell line1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID201293Inhibition of in vitro cell growth which reduces cell growth to 50% of level at start of experiment in CNS SF-539 cell line(<-4 in one experiment, >-4 in other experiment)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]